Executive Summary
A single neutral deobligation alert for NASA's $109M delivery order to Caltech (JPL operator) signals stable long-term space R&D funding through 2028, with $90M already outlayed. Limited direct equity implications due to nonprofit recipient, but unexercised $16M options offer minor upside. Execution risks persist from task order dependence, warranting sector-level monitoring in aerospace R&D.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Deobligations Alert digest from March 15, 2026.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Long performance period to 2028-09-30 with dependence on future NASA task orders for full obligation realization.
Opportunities (1)
- ◆
Unexercised options worth $16M to reach $125M ceiling; continued JPL FFRDC sponsorship enabling additional NASA task orders.
Sector Themes (1)
- ◆
NASA's $109M deobligation on Caltech/JPL order reflects ongoing sponsorship of critical space science via nonprofits over 10-year horizon.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL NASA Contracts", "reason"=>"$109M deobligation with $16M options and $90M outlays signals potential for further adjustments in space R&D funding.", "trigger"=>"Option exercises or new delivery orders exceeding $125M ceiling"}
Get daily alerts with 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Deobligations Alert
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals